enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming genetic medicines. We are unlocking the promise of gene therapy for more patients through localized delivery of non-viral treatments. Founded in Canada, with a United States headquarters in the greater Boston area, our mission is to deliver innovative, locally administered, non-viral genetic medicines to address diseases of high clinical need, including non-muscle invasive bladder cancer (NMIBC), a disease with significant patient burden and massive healthcare system economic impact. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with non-muscle invasive bladder cancer (NMIBC) in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region.
enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming genetic medicines. We are unlocking the promise of gene therapy for more patients through localized delivery of non-viral treatments. Founded in Canada, with a United States headquarters in the greater Boston area, our mission is to deliver innovative, locally administered, non-viral genetic medicines to address diseases of high clinical need, including non-muscle invasive bladder cancer (NMIBC), a disease with significant patient burden and massive healthcare system economic impact. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with non-muscle invasive bladder cancer (NMIBC) in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region.
Company Information
- Industry
- Company Type
- Public Company
- Founded
- 1999
- Employee Range
- 51-200
- Revenue Range
- Not available
Location
- Address
- 200 5th Ave Massachusetts Waltham
- City
- Region
- Postal Code
- 02451
- Country
- Canada